RhumbLine Advisers’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.61M | Buy |
186,099
+5,025
| +3% | +$70.5K | ﹤0.01% | 1744 |
|
|
2025
Q1 | $2.83M | Buy |
181,074
+13,022
| +8% | +$204K | ﹤0.01% | 1638 |
|
|
2024
Q4 | $2.34M | Buy |
168,052
+4,598
| +3% | +$64.1K | ﹤0.01% | 1802 |
|
|
2024
Q3 | $1.52M | Sell |
163,454
-3,835
| -2% | -$35.7K | ﹤0.01% | 2046 |
|
|
2024
Q2 | $1.56M | Buy |
167,289
+41,956
| +33% | +$390K | ﹤0.01% | 2017 |
|
|
2024
Q1 | $1.24M | Buy |
125,333
+18,402
| +17% | +$182K | ﹤0.01% | 2132 |
|
|
2023
Q4 | $345K | Buy |
106,931
+27,501
| +35% | +$88.8K | ﹤0.01% | 2893 |
|
|
2023
Q3 | $422K | Buy |
79,430
+878
| +1% | +$4.66K | ﹤0.01% | 2710 |
|
|
2023
Q2 | $749K | Buy |
78,552
+24,386
| +45% | +$232K | ﹤0.01% | 2452 |
|
|
2023
Q1 | $596K | Buy |
54,166
+789
| +1% | +$8.68K | ﹤0.01% | 2369 |
|
|
2022
Q4 | $790K | Buy |
53,377
+8,703
| +19% | +$129K | ﹤0.01% | 2254 |
|
|
2022
Q3 | $854K | Buy |
44,674
+3,329
| +8% | +$63.6K | ﹤0.01% | 2229 |
|
|
2022
Q2 | $881K | Buy |
41,345
+6,005
| +17% | +$128K | ﹤0.01% | 2205 |
|
|
2022
Q1 | $681K | Sell |
35,340
-262
| -0.7% | -$5.05K | ﹤0.01% | 2280 |
|
|
2021
Q4 | $738K | Buy |
35,602
+18
| +0.1% | +$373 | ﹤0.01% | 2338 |
|
|
2021
Q3 | $850K | Buy |
35,584
+1,300
| +4% | +$31.1K | ﹤0.01% | 2300 |
|
|
2021
Q2 | $936K | Buy |
34,284
+14,151
| +70% | +$386K | ﹤0.01% | 2274 |
|
|
2021
Q1 | $582K | Buy |
20,133
+45
| +0.2% | +$1.3K | ﹤0.01% | 2417 |
|
|
2020
Q4 | $565K | Buy |
20,088
+3,113
| +18% | +$87.6K | ﹤0.01% | 2394 |
|
|
2020
Q3 | $497K | Buy |
16,975
+5,944
| +54% | +$174K | ﹤0.01% | 2291 |
|
|
2020
Q2 | $334K | Buy |
11,031
+1,150
| +12% | +$34.8K | ﹤0.01% | 2525 |
|
|
2020
Q1 | $294K | Buy |
+9,881
| New | +$294K | ﹤0.01% | 2419 |
|